2019年欧洲抗风湿病联盟对系统性红斑狼疮治疗推荐更新意见的解读
|
摘要
欧洲抗风湿病联盟(the European League Against Rheumatism,EULAR)于2008年2月发布第1版针对系统性红斑狼疮(systemic lupus erythematosus,SLE)的治疗推荐,被普遍认可并广泛应用于临床。在此基础上EULAR多次更新并完善了SLE疾病监测、并发症防治及妊娠管理等多方面内容。2019年3月,EULAR再次对SLE治疗推荐进行更新,本次重点更新了首要原则、生物制剂使用、个体化治疗方案及多靶点治疗策略,这为SLE规范化和个体化的"达标治疗"奠定了良好的基础。
The European League Against Rheumatism(EULAR) issued the first edition of the treatment recommendation for systemic lupus erythematosus in February 2008, which is widely recognized and used in clinical practice. On this basis, the recommendation was updated repeatedly by EULAR to improve the disease monitoring and prevention of complications, pregnancy management and many other aspects. In March 2019, EULAR updated the treatment recommendation for SLE, which focusing on updating the first principles, the use of biological agents, individualized treatment programs and multi-target treatment strategies. This laid a good foundation for standardization and individualization of SLE treatment.
The European League Against Rheumatism(EULAR) issued the first edition of the treatment recommendation for systemic lupus erythematosus in February 2008, which is widely recognized and used in clinical practice. On this basis, the recommendation was updated repeatedly by EULAR to improve the disease monitoring and prevention of complications, pregnancy management and many other aspects. In March 2019, EULAR updated the treatment recommendation for SLE, which focusing on updating the first principles, the use of biological agents, individualized treatment programs and multi-target treatment strategies. This laid a good foundation for standardization and individualization of SLE treatment.
引文
[1]Bertsias G,Ioannidis JP,Boletis J, et al.EULAR recommendations for the management of systemic lupus erythematosus.Report of a Task Force of the EULAR standing Committee for international clinical studies including therapeutics[J].Ann Rheum Dis,2008,67(2):195-205.
[2]Mosca M,Tani C,Aringer M,et al. EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies[J].Ann Rheum Dis,2009,69(7):1269-1274.
[3]Bertsias GK,Ioannidis JP,Aringer M,et al.EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations:report of a task force of the eular standing committee for clinical affairs[J].Ann Rheum Dis,2010,69(12):2074-2082.
[4]van der Heijde D,Aletaha D, Carmona L,et al. 2014 update of the EULARstandardised operating procedures for EULARendorsed recommendations[J].Ann Rheum Dis,2015,74(1):8-13.
[5]Andreoli L,Bertsias GK,Agmon-Levin N,et al.EULAR recommendations for women's health and the management of family planning,assisted reproduction,pregnancy andmenopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome[J].Ann Rheum Dis,2017.76(3):476-485.
[6]Fanouriakis A,Kostopoulou M,Alunno A,et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J].Ann Rheum Dis,2019,78(6):736-745.
[7]van Vollenhoven RF,Mosca M,Bertsias G,et al. Treat-totarget in systemic lupus erythematosus:recommendations from an international task force[J].Ann Rheum Dis,2014,73(6):958-967.
[8]Michaud M,Catros F,Ancellin S,et al. Treatment of systemic lupus erythematosus:don't forget hydroxychloroquine[J].Ann Rheum Dis,2019,doi:10.113 6/annrheumdis-2019-215799.
[9]Jesus D,Rodrigues M,da Silva JAP,et al.Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis[J].Lupus,2018,27(8):13 58-1362.
[10]Zhang H,Liu Z,Zhou M,et al.Multitarget therapy for maintenance treatment of lupus nephritis[J].J Am Soc Nephrol, 2017,28(12):3671-3678.
[2]Mosca M,Tani C,Aringer M,et al. EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies[J].Ann Rheum Dis,2009,69(7):1269-1274.
[3]Bertsias GK,Ioannidis JP,Aringer M,et al.EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations:report of a task force of the eular standing committee for clinical affairs[J].Ann Rheum Dis,2010,69(12):2074-2082.
[4]van der Heijde D,Aletaha D, Carmona L,et al. 2014 update of the EULARstandardised operating procedures for EULARendorsed recommendations[J].Ann Rheum Dis,2015,74(1):8-13.
[5]Andreoli L,Bertsias GK,Agmon-Levin N,et al.EULAR recommendations for women's health and the management of family planning,assisted reproduction,pregnancy andmenopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome[J].Ann Rheum Dis,2017.76(3):476-485.
[6]Fanouriakis A,Kostopoulou M,Alunno A,et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J].Ann Rheum Dis,2019,78(6):736-745.
[7]van Vollenhoven RF,Mosca M,Bertsias G,et al. Treat-totarget in systemic lupus erythematosus:recommendations from an international task force[J].Ann Rheum Dis,2014,73(6):958-967.
[8]Michaud M,Catros F,Ancellin S,et al. Treatment of systemic lupus erythematosus:don't forget hydroxychloroquine[J].Ann Rheum Dis,2019,doi:10.113 6/annrheumdis-2019-215799.
[9]Jesus D,Rodrigues M,da Silva JAP,et al.Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis[J].Lupus,2018,27(8):13 58-1362.
[10]Zhang H,Liu Z,Zhou M,et al.Multitarget therapy for maintenance treatment of lupus nephritis[J].J Am Soc Nephrol, 2017,28(12):3671-3678.